Group 1 - The core viewpoint of the report is that Jingfeng Medical-B (02675) is rated as "Buy" with projected revenues of 4.32 billion, 8.11 billion, and 12.36 billion yuan for 2025-2027, respectively, and a target price of 73.20 yuan/79.57 HKD based on a 35X PS for 2026 [1] - Jingfeng Medical is a leader in the domestic surgical robot market, continuously innovating to drive technological advancements, having established a "three-in-one" surgical solution with multi-port, single-port, and natural orifice surgical robots [1] - The company has achieved significant milestones, being the first in China and the second globally to obtain regulatory approval for multiple types of surgical robots, with its MSP2000 system receiving CE certification in October 2025 [1] Group 2 - Since the commercialization of its multi-port surgical robot in December 2022, Jingfeng Medical has sold 20 units in 2024, ranking first among domestic manufacturers, with clinical applications covering over 220 hospitals across 30 provinces [2] - The company's total revenue is projected to increase from 48 million yuan in 2023 to 160 million yuan in 2024, and from 30 million yuan in H1 2024 to 149 million yuan in H1 2025 [2] Group 3 - In 2024, Jingfeng Medical successfully entered the overseas market, quickly securing 5 orders and establishing a global distribution network covering five continents [3] - By H1 2025, the company had 30 distributors, including 10 overseas, and signed global sales agreements for 118 units of core products, with 72 units designated for international markets, marking a significant step in its globalization efforts [3]